Scarica l'app Stockscreener
287.03
0.11%
-0.33
Dopo l'orario di chiusura:
287.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$287.36
Aprire:
$286.03
Volume 24 ore:
320.30K
Relative Volume:
0.49
Capitalizzazione di mercato:
$20.19B
Reddito:
$2.36B
Utile/perdita netta:
$236.10M
Rapporto P/E:
87.35
EPS:
3.286
Flusso di cassa netto:
$382.50M
1 W Prestazione:
+0.54%
1M Prestazione:
-12.27%
6M Prestazione:
-8.32%
1 anno Prestazione:
+8.99%
Intervallo 1D:
$285.20
$287.53
Intervallo di 1 settimana:
$285.08
$290.60
Portata 52W:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Confronta PODD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
287.03 | 20.21B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
125.78 | 216.61B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.01 | 141.96B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.12 | 134.80B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.66 | 123.27B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.20 | 50.45B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
From Edwards to Insulet: Three key medical device cases of 2025 - Life Sciences Intellectual Property Review
Insulet Corporation (NASDAQ:PODD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Swedbank AB Buys 5,000 Shares of Insulet Corporation $PODD - MarketBeat
Osaic Holdings Inc. Purchases 5,309 Shares of Insulet Corporation $PODD - MarketBeat
Beacon Investment Advisory Services Inc. Has $25.11 Million Stake in Insulet Corporation $PODD - MarketBeat
3 Reasons Growth Investors Will Love Insulet (PODD) - sharewise.com
Insulet Corporation $PODD Holdings Decreased by Squarepoint Ops LLC - MarketBeat
Insulet Corporation $PODD Shares Acquired by Munro Partners - MarketBeat
Insulet Corp. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Insulin Delivery Devices Market Outlook: Market to Reach US$ - openPR.com
Patton Fund Management Inc. Buys 13,972 Shares of Insulet Corporation $PODD - MarketBeat
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com
Insulet Corporation's (NASDAQ:PODD) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 - Insider Monkey
Is Insulet Fairly Priced After Its Strong Run and High Earnings Multiple in 2025? - simplywall.st
Voya Investment Management LLC Has $19.59 Million Stock Holdings in Insulet Corporation $PODD - MarketBeat
(PODD) Risk Channels and Responsive Allocation - Stock Traders Daily
Tubeless Insulin Pumps Market Size, Share, Trends | Top - openPR.com
Congress Asset Management Co. Acquires 9,976 Shares of Insulet Corporation $PODD - MarketBeat
Why Insulet Corporation (GOV) stock is a strong analyst pick2025 Technical Patterns & AI Powered Market Entry Strategies - Улправда
Perpetual Ltd Sells 5,898 Shares of Insulet Corporation $PODD - MarketBeat
Should Insulet’s (PODD) Expanded Pod Recycling Effort Reframe Its Long‑Term Sustainability Edge? - Yahoo Finance UK
Guidance Update: Can Insulet Corporation (GOV) stock sustain revenue momentum2025 Growth vs Value & Weekly Breakout Watchlists - moha.gov.vn
Insulet appoints PwC as new auditor for 2026, replaces Grant Thornton By Investing.com - Investing.com Nigeria
Insulet appoints PwC as new auditor for 2026, replaces Grant Thornton - Investing.com Nigeria
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Returns Recap: Will Insulet Corporation stock outperform value stocksIPO Watch & Risk Controlled Daily Trade Plans - Улправда
Why analysts upgrade Insulet Corporation stockTrade Analysis Summary & Free Accurate Trade Setup Notifications - DonanımHaber
FOMO Trade: Why Insulet Corporation stock attracts high net worth investorsJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - Улправда
Why institutional investors increase stakes in Insulet Corporation (GOV) stockJuly 2025 Intraday Action & Expert Approved Trade Ideas - DonanımHaber
Texas Permanent School Fund Corp Purchases 3,633 Shares of Insulet Corporation $PODD - MarketBeat
Why Insulet Corporation stock attracts global investorsExit Point & Short-Term Swing Trade Alerts - Улправда
Assenagon Asset Management S.A. Raises Stock Position in Insulet Corporation $PODD - MarketBeat
Is Insulet Corporation (GOV) stock positioned for digital growth era2025 Risk Factors & Low Drawdown Investment Ideas - DonanımHaber
What margin trends mean for Insulet Corporation stockJuly 2025 Technicals & Growth-Oriented Investment Plans - DonanımHaber
Insulet Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Insulet stock price target lowered to $203 by BofA Securities - Investing.com South Africa
Insulet’s New Omnipod M Study Targets the Untapped Type 2 Diabetes Pump Market - TipRanks
Insulet stock price target maintained at $400 by UBS on growth outlook - Investing.com Nigeria
Insulet (PODD) Analyst Rating Update: Truist Securities Lowers P - GuruFocus
Truist Financial Issues Pessimistic Forecast for Insulet (NASDAQ:PODD) Stock Price - MarketBeat
Truist Securities Lowers Price Target on Insulet to $390 From $412, Maintains Buy Rating - marketscreener.com
UBS Reiterates Buy Rating on Insulet Corporation (PODD) - StreetInsider
Evercore ISI Begins Coverage on Insulet (NASDAQ:PODD) - MarketBeat
Why Insulet Corporation stock attracts high net worth investorsIndex Update & Risk Controlled Swing Alerts - Улправда
Insulet Corporation (PODD) PT Lowered to $203 at BofA Securities - StreetInsider
Central Pacific Bank Trust Division Reduces Stock Holdings in Insulet Corporation $PODD - MarketBeat
Is Insulet stock underperforming the Nasdaq? - MSN
Insulet Corporation (PODD) Announces Amendments to Annual Incentive Plan - GuruFocus
A Look Into Insulet Inc's Price Over Earnings - Sahm
Insulet Corporation (PODD) revises Annual Incentive Plan terms for 2026 - Stock Titan
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):